Sinopharm Tech Holdings (HKSE:08156) Interest Expense: HK$-4.61 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:08156 Sinopharm Tech Holdings Ltd HKSE:08156
24 GF Score
Price HK$0.21
GF Value HK$0.06
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Sinopharm Tech Holdings Interest Expense?

Sinopharm Tech Holdings HKSE:08156 +12.37% 24 Interest Expense is HK$-4.61 Mil as of Dec. 2025. GuruFocus rates HKSE:08156 with a GF Score™ of 24/100 and a GF Value™ of HK$0.06 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Sinopharm Tech Holdings's interest expense for the six months ended in Dec. 2025 was HK$ -2.14 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-4.61 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Sinopharm Tech Holdings's Operating Income for the six months ended in Dec. 2025 was HK$ -1.55 Mil. Sinopharm Tech Holdings's Interest Expense for the six months ended in Dec. 2025 was HK$ -2.14 Mil. Sinopharm Tech Holdings did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Sinopharm Tech Holdings  (HKSE:08156) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Sinopharm Tech Holdings's Interest Expense for the six months ended in Dec. 2025 was HK$-2.14 Mil. Its Operating Income for the six months ended in Dec. 2025 was HK$-1.55 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Dec. 2025 was HK$0.00 Mil.

Sinopharm Tech Holdings's Interest Coverage for the quarter that ended in Dec. 2025 is calculated as

Sinopharm Tech Holdings did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Sinopharm Tech Holdings Interest Expense Historical Data

* Premium members only.

The historical data trend for Sinopharm Tech Holdings's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sinopharm Tech Holdings Interest Expense Chart

Sinopharm Tech Holdings Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -14.55 -16.41 -8.57 -23.93 -5.85

Sinopharm Tech Holdings Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.89 -22.04 -3.38 -2.47 -2.14
HKSE:08156
24GF Score
Sinopharm Tech Holdings Ltd HKSE:08156
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sinopharm Tech Holdings Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-4.61 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of HK$-4.61 Mil mean?
Sinopharm Tech Holdings (HKSE:08156) has a Interest Expense of HK$-4.61 Mil as of Dec. 2025. Interest Expense is the amount a company pays on its long-term debt. View historical data on Sinopharm Tech Holdings and its competitors.
Is Sinopharm Tech Holdings' Interest Expense too high?
Sinopharm Tech Holdings' current Interest Expense is HK$-4.61 Mil. Overall, Sinopharm Tech Holdings has a GF Score™ of 24/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sinopharm Tech Holdings' Interest Expense compare to CRM and SHOP?
Sinopharm Tech Holdings' Interest Expense of HK$-4.61 Mil can be compared against companies in the Software industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Software company?
A good Interest Expense depends on the Software industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Sinopharm Tech Holdings and its competitors. Sinopharm Tech Holdings's current Interest Expense is HK$-4.61 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinopharm Tech Holdings stock overvalued right now?
Based on GuruFocus' analysis, Sinopharm Tech Holdings (HKSE:08156) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.06, compared to a current price of HK$0.21 — trading 248.3% above its estimated fair value. The current Interest Expense is HK$-4.61 Mil. Sinopharm Tech Holdings' overall GF Score™ is 24/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Sinopharm Tech Holdings (HKSE:08156), the current Interest Expense is HK$-4.61 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sinopharm Tech Holdings (HKSE:08156) Overvalued in 2026?

Based on GuruFocus' analysis, Sinopharm Tech Holdings stock appears to be overvalued. The current stock price of HK$0.21 is trading 248.3% above its estimated GF Value™ of HK$0.06. GuruFocus considers Sinopharm Tech Holdings to be Significantly Overvalued.

Key valuation signals for HKSE:08156:

  • Interest Expense: HK$-4.61 Mil
  • GF Value™: HK$0.06 vs. price of HK$0.21 (248.3% above fair value)
  • GF Score™: 24/100 with 6 warning signs

No single metric tells the full story. See the HKSE:08156 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sinopharm Tech Holdings Business Description

Address Ruttonjee Centre, 11 Duddell Street Central, Unit 1802, 18th Floor, Ruttonjee House, Hong Kong, HKG
Sinopharm Tech Holdings Ltd is an investment holding company operating through three segments: Internet Plus services, Supply Chain services, and Manufacturing and distribution of personal protective equipment. The company generates the majority of its revenue from the Supply Chain services segment, which includes supply chain management, data analysis, and trading of medical and related products. Geographically, it operates in Hong Kong and the People's Republic of China (PRC), with the majority of its revenue coming from the PRC.
24GF Score

Get the complete analysis for HKSE:08156

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$0.21
Price
HK$0.06
GF Value